MedTrace Logo

Convalescent Plasma for COVID-19 Patients

NCT04516954 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-06-06

No results posted yet for this study

Summary

The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. The first phase is to test the safety of CP therapy.

Conditions

  • COVID 19

Interventions

BIOLOGICAL

Convalescent COVID 19 Plasma

A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject

Sponsors & Collaborators

  • National Institute of Hygiene and Epidemiology, Vietnam

    collaborator OTHER

  • National Hospital for Tropical Diseases, Hanoi, Vietnam

    collaborator OTHER_GOV

  • National Institute of Hematology and Blood Transfusion, Vietnam

    collaborator OTHER

  • Vinmec Research Institute of Stem Cell and Gene Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-03-30
Completion
2021-04-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516954 on ClinicalTrials.gov